These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 27740635)
1. A novel signalling screen demonstrates that CALR mutations activate essential MAPK signalling and facilitate megakaryocyte differentiation. Kollmann K; Warsch W; Gonzalez-Arias C; Nice FL; Avezov E; Milburn J; Li J; Dimitropoulou D; Biddie S; Wang M; Poynton E; Colzani M; Tijssen MR; Anand S; McDermott U; Huntly B; Green T Leukemia; 2017 Apr; 31(4):934-944. PubMed ID: 27740635 [TBL] [Abstract][Full Text] [Related]
2. Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion. Han L; Schubert C; Köhler J; Schemionek M; Isfort S; Brümmendorf TH; Koschmieder S; Chatain N J Hematol Oncol; 2016 May; 9(1):45. PubMed ID: 27177927 [TBL] [Abstract][Full Text] [Related]
3. Skewed megakaryopoiesis in human induced pluripotent stem cell-derived haematopoietic progenitor cells harbouring calreticulin mutations. Takei H; Edahiro Y; Mano S; Masubuchi N; Mizukami Y; Imai M; Morishita S; Misawa K; Ochiai T; Tsuneda S; Endo H; Nakamura S; Eto K; Ohsaka A; Araki M; Komatsu N Br J Haematol; 2018 Jun; 181(6):791-802. PubMed ID: 29741776 [TBL] [Abstract][Full Text] [Related]
4. CALR frameshift mutations in MPN patient-derived iPSCs accelerate maturation of megakaryocytes. Olschok K; Han L; de Toledo MAS; Böhnke J; Graßhoff M; Costa IG; Theocharides A; Maurer A; Schüler HM; Buhl EM; Pannen K; Baumeister J; Kalmer M; Gupta S; Boor P; Gezer D; Brümmendorf TH; Zenke M; Chatain N; Koschmieder S Stem Cell Reports; 2021 Nov; 16(11):2768-2783. PubMed ID: 34678208 [TBL] [Abstract][Full Text] [Related]
5. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable. Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496 [TBL] [Abstract][Full Text] [Related]
6. MPL overexpression induces a high level of mutant-CALR/MPL complex: a novel mechanism of ruxolitinib resistance in myeloproliferative neoplasms with CALR mutations. Yasuda S; Aoyama S; Yoshimoto R; Li H; Watanabe D; Akiyama H; Yamamoto K; Fujiwara T; Najima Y; Doki N; Sakaida E; Edahiro Y; Imai M; Araki M; Komatsu N; Miura O; Kawamata N Int J Hematol; 2021 Oct; 114(4):424-440. PubMed ID: 34165774 [TBL] [Abstract][Full Text] [Related]
15. The Synergistic Inhibitory Effect of Combining MK-2206 and AZD 6244 in MARIMO Cells Harboring a Calreticulin Gene Mutation. Wang C; Hu X; Wan Y; Wang S; Qi K; Li Y; Qiao J; Zeng L; Li Z; Fu C; Xu K Chemotherapy; 2021; 66(5-6):169-178. PubMed ID: 34666331 [TBL] [Abstract][Full Text] [Related]
16. The prevalence of CALR mutations in a cohort of patients with myeloproliferative neoplasms. Grinsztejn E; Percy MJ; McClenaghan D; Quintana M; Cuthbert RJ; McMullin MF Int J Lab Hematol; 2016 Feb; 38(1):102-6. PubMed ID: 26555437 [TBL] [Abstract][Full Text] [Related]
17. Simultaneous screening for JAK2 and calreticulin gene mutations in myeloproliferative neoplasms with high resolution melting. Matsumoto N; Mori S; Hasegawa H; Sasaki D; Mori H; Tsuruda K; Imanishi D; Imaizumi Y; Hata T; Kaku N; Kosai K; Uno N; Miyazaki Y; Yanagihara K Clin Chim Acta; 2016 Nov; 462():166-173. PubMed ID: 27693531 [TBL] [Abstract][Full Text] [Related]
18. Validation of a molecular diagnostic assay for CALR exon 9 indels in myeloproliferative neoplasms: identification of coexisting JAK2 and CALR mutations and a novel 9 bp deletion in CALR. Murugesan G; Guenther-Johnson J; Mularo F; Cook JR; Daly TM Int J Lab Hematol; 2016 Jun; 38(3):284-97. PubMed ID: 27018326 [TBL] [Abstract][Full Text] [Related]
19. CAL2 Immunohistochemical Staining Accurately Identifies CALR Mutations in Myeloproliferative Neoplasms. Nomani L; Bodo J; Zhao X; Durkin L; Loghavi S; Hsi ED Am J Clin Pathol; 2016 Oct; 146(4):431-8. PubMed ID: 27686170 [TBL] [Abstract][Full Text] [Related]
20. Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratory. Agarwal R; Blombery P; McBean M; Jones K; Fellowes A; Doig K; Forsyth C; Westerman DA Ann Hematol; 2017 May; 96(5):725-732. PubMed ID: 28161773 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]